FEMASYS INCFEMY

FEMASYS INC Segments Disclosure

10-KFiled Mar 31, 20261 min read
(14)
Segment Reporting
 
In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (infertility and permanent birth control).
 
The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net loss attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.
 
 Significant segment expenses, as provided to the CODM are as follows:
 
         
    2025     2024  
Sales
 $2,293,313    1,629,108 
Cost of sales (excluding depreciation expense)
  872,400    544,903 
Research and development expense
  2,072,771    2,217,610 
Other research and development expenses
  5,504,933    5,998,933 
Total research and development expense
  7,577,704    8,216,543 
Sales and marketing expense
  4,443,807    4,030,150 
General and administrative expense
  6,646,037    6,325,999 
Depreciation and amortization expense
  342,034    297,318 
Total operating expenses
  19,009,582    18,870,010 
Total other expense
  (1,037,921)    (1,021,221) 
Loss before income taxes
  (18,626,590)    (18,807,026) 
Income tax expense
  1,297    9,602 
Net loss
 $(18,627,887)    (18,816,628) 
 
1
Other research and development expenses include clinical affairs, regulatory, manufacturing and quality assurance expenses.

Historical Timeline

Fiscal YearFiled
2025Mar 31, 2026Showing above
2024Mar 27, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&EDebtCommitmentsStock CompensationNew StandardsPay vs Performance